BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 36379120)

  • 1. Disorders of cancer metabolism: The therapeutic potential of cannabinoids.
    Sun D; Li X; Nie S; Liu J; Wang S
    Biomed Pharmacother; 2023 Jan; 157():113993. PubMed ID: 36379120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Caffeic Acid Targets AMPK Signaling and Regulates Tricarboxylic Acid Cycle Anaplerosis while Metformin Downregulates HIF-1α-Induced Glycolytic Enzymes in Human Cervical Squamous Cell Carcinoma Lines.
    Tyszka-Czochara M; Bukowska-Strakova K; Kocemba-Pilarczyk KA; Majka M
    Nutrients; 2018 Jun; 10(7):. PubMed ID: 29958416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. ROS/PI3K/Akt and Wnt/β-catenin signalings activate HIF-1α-induced metabolic reprogramming to impart 5-fluorouracil resistance in colorectal cancer.
    Dong S; Liang S; Cheng Z; Zhang X; Luo L; Li L; Zhang W; Li S; Xu Q; Zhong M; Zhu J; Zhang G; Hu S
    J Exp Clin Cancer Res; 2022 Jan; 41(1):15. PubMed ID: 34998404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recent advances in the role of AMP-activated protein kinase in metabolic reprogramming of metastatic cancer cells: targeting cellular bioenergetics and biosynthetic pathways for anti-tumor treatment.
    Tyszka-Czochara M; Konieczny P; Majka M
    J Physiol Pharmacol; 2018 Jun; 69(3):. PubMed ID: 30279304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salvianolic acid B inhibits glycolysis in oral squamous cell carcinoma via targeting PI3K/AKT/HIF-1α signaling pathway.
    Wei J; Wu J; Xu W; Nie H; Zhou R; Wang R; Liu Y; Tang G; Wu J
    Cell Death Dis; 2018 May; 9(6):599. PubMed ID: 29789538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Aerobic Glycolysis Represses Akt/mTOR/HIF-1α Axis and Restores Tamoxifen Sensitivity in Antiestrogen-Resistant Breast Cancer Cells.
    Woo YM; Shin Y; Lee EJ; Lee S; Jeong SH; Kong HK; Park EY; Kim HK; Han J; Chang M; Park JH
    PLoS One; 2015; 10(7):e0132285. PubMed ID: 26158266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncogenic regulation of tumor metabolic reprogramming.
    Tarrado-Castellarnau M; de Atauri P; Cascante M
    Oncotarget; 2016 Sep; 7(38):62726-62753. PubMed ID: 28040803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The sweet trap in tumors: aerobic glycolysis and potential targets for therapy.
    Yu L; Chen X; Wang L; Chen S
    Oncotarget; 2016 Jun; 7(25):38908-38926. PubMed ID: 26918353
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wortmannin influences hypoxia-inducible factor-1 alpha expression and glycolysis in esophageal carcinoma cells.
    Zeng L; Zhou HY; Tang NN; Zhang WF; He GJ; Hao B; Feng YD; Zhu H
    World J Gastroenterol; 2016 May; 22(20):4868-80. PubMed ID: 27239113
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NOX4-Derived ROS Mediates TGF-
    Su X; Yang Y; Guo C; Zhang R; Sun S; Wang Y; Qiao Q; Fu Y; Pang Q
    Oxid Med Cell Longev; 2021; 2021():5549047. PubMed ID: 34257808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lipid metabolic reprogramming by hypoxia-inducible factor-1 in the hypoxic tumour microenvironment.
    Seo J; Yun JE; Kim SJ; Chun YS
    Pflugers Arch; 2022 Jun; 474(6):591-601. PubMed ID: 35348849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AMP-activated protein kinase activity is required for vanadate-induced hypoxia-inducible factor 1alpha expression in DU145 cells.
    Hwang JT; Lee M; Jung SN; Lee HJ; Kang I; Kim SS; Ha J
    Carcinogenesis; 2004 Dec; 25(12):2497-507. PubMed ID: 15297373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Loss of the tumor suppressor LKB1 promotes metabolic reprogramming of cancer cells via HIF-1α.
    Faubert B; Vincent EE; Griss T; Samborska B; Izreig S; Svensson RU; Mamer OA; Avizonis D; Shackelford DB; Shaw RJ; Jones RG
    Proc Natl Acad Sci U S A; 2014 Feb; 111(7):2554-9. PubMed ID: 24550282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The interferon-inducible protein viperin controls cancer metabolic reprogramming to enhance cancer progression.
    Choi KM; Kim JJ; Yoo J; Kim KS; Gu Y; Eom J; Jeong H; Kim K; Nam KT; Park YS; Chung JY; Seo JY
    J Clin Invest; 2022 Dec; 132(24):. PubMed ID: 36227691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
    Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
    Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic phenotype of bladder cancer.
    Massari F; Ciccarese C; Santoni M; Iacovelli R; Mazzucchelli R; Piva F; Scarpelli M; Berardi R; Tortora G; Lopez-Beltran A; Cheng L; Montironi R
    Cancer Treat Rev; 2016 Apr; 45():46-57. PubMed ID: 26975021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Orexin A affects HepG2 human hepatocellular carcinoma cells glucose metabolism via HIF-1α-dependent and -independent mechanism.
    Wan X; Liu Y; Zhao Y; Sun X; Fan D; Guo L
    PLoS One; 2017; 12(9):e0184213. PubMed ID: 28886081
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo.
    Faubert B; Boily G; Izreig S; Griss T; Samborska B; Dong Z; Dupuy F; Chambers C; Fuerth BJ; Viollet B; Mamer OA; Avizonis D; DeBerardinis RJ; Siegel PM; Jones RG
    Cell Metab; 2013 Jan; 17(1):113-24. PubMed ID: 23274086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The tumor suppressor folliculin regulates AMPK-dependent metabolic transformation.
    Yan M; Gingras MC; Dunlop EA; Nouët Y; Dupuy F; Jalali Z; Possik E; Coull BJ; Kharitidi D; Dydensborg AB; Faubert B; Kamps M; Sabourin S; Preston RS; Davies DM; Roughead T; Chotard L; van Steensel MA; Jones R; Tee AR; Pause A
    J Clin Invest; 2014 Jun; 124(6):2640-50. PubMed ID: 24762438
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.